NightHawk lays off 14% of R&D work­force, piv­ots to fo­cus on CD­MO Scor­pius Bio­man­u­fac­tur­ing

NightHawk Bio­sciences laid off 14% of its work­force in R&D in or­der to fo­cus on its con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion (CD­MO), just a lit­tle over a month af­ter the com­pa­ny’s CEO said it was con­tin­u­ing its R&D ac­tiv­i­ties and was “high­ly en­cour­aged” by pre­clin­i­cal da­ta.

The de­ci­sion to lay off 13 em­ploy­ees was made af­ter the board of di­rec­tors ap­proved a “re­fo­cus and re­struc­tur­ing plan” to axe “non-core as­sets” and re­duce op­er­at­ing costs, as NightHawk builds up its CD­MO Scor­pius Bio­man­u­fac­tur­ing, the com­pa­ny said in SEC fil­ings Tues­day. 

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER